MBHB Partner Kevin Noonan Authors BioPharm Int’l. Article Entitled, “The Costs of Commercializing CRISPR”

McDonnell Boehnen Hulbert & Berghoff LLP partner Kevin Noonan, Ph.D. authors BioPharm International article dated March 1, 2020, entitled, “The Costs of Commercializing CRISPR.” As patent disputes within the scientific community continue, drug developers consider the intellectual property unknowns associated with this emerging technology. view the article